Treatment of Leishmaniasis

Introduction to Leishmaniasis Treatment

The American College of Physicians and Infectious Diseases Society of America recommends sodium stibogluconate as first-line therapy for leishmaniasis in areas with low antimony resistance (<10%), while itraconazole has insufficient evidence to support its routine use for leishmaniasis treatment 1, 2, 3

Sodium Stibogluconate (SSG) Treatment

Pentavalent antimonials, including sodium stibogluconate, have been the mainstay of leishmaniasis treatment for approximately 7 decades, showing good efficacy against most Leishmania species in most geographic regions 4
For visceral leishmaniasis (VL), SSG is recommended at 20 mg SbV/kg/day IV or IM for 28 days in areas with low antimony resistance 2, 3
Efficacy rates exceed 90-95% for both L. infantum-chagasi and L. donovani infection in East Africa, Brazil, and Greece 1, 3
For cutaneous leishmaniasis (CL), the traditional regimen is 20 mg SbV/kg/day for 20 days 4

Administration Routes and Efficacy

Intravenous (IV) and intramuscular (IM) routes are most common in North America 4
Therapeutic failures have been reported, especially in northeast India, Bangladesh, Nepal, and Bhutan 1, 3
Concerns about toxicity have led to the emergence of liposomal amphotericin B (L-AmB) and miltefosine as first-line drugs in some regions 1, 3

Itraconazole Treatment

There are only published case reports and small clinical series with imidazole antifungals (fluconazole or itraconazole) with/without allopurinol in persons with VL 1, 3
The available data are insufficient to recommend itraconazole's use for visceral leishmaniasis 1, 3
Specific data on itraconazole's efficacy in leishmaniasis is limited in the available guidelines 1, 2, 3

Treatment Algorithm

For Visceral Leishmaniasis: First-line in areas with low antimony resistance (<10%): Sodium stibogluconate 20 mg SbV/kg/day IV or IM for 28 days 2, 3
For Visceral Leishmaniasis: First-line in areas with high antimony resistance or when SSG is contraindicated: Liposomal amphotericin B (L-AmB) 1, 5
Itraconazole is not recommended as monotherapy due to insufficient evidence 1, 3

Monitoring and Alternative Therapies

Clinical parameters correlate well with parasitologic responses to VL treatment and should be used to monitor the response 1, 3
Avoid switching to amphotericin B deoxycholate in persons with contraindications to or substantial toxicity with L-AmB, as it is almost always associated with more toxicity 1, 3
Do not use intralesional SSG on fingers, nose, ears, eyelids, near lips, or areas where vascular compromise could be concerning 6

Treatment of Leishmaniasis

Visceral Leishmaniasis (VL) Treatment

The Infectious Diseases Society of America recommends liposomal amphotericin B (L-AmB) as the first-line therapy for visceral leishmaniasis in immunocompetent persons, with an FDA-approved dosage regimen of 3 mg/kg/day IV on days 1-5, 14, and 21 (total dose: 21 mg/kg) 7, 8, 9
For immunosuppressed persons with VL, including those with HIV/AIDS, L-AmB is recommended at 4 mg/kg/day IV on days 1-5, 10, 17, 24, 31, and 38 (total dose: 40 mg/kg) 10, 11
Higher doses (≥40 mg/kg) of L-AmB may be necessary for VL acquired in East Africa 8

Cutaneous Leishmaniasis (CL) Treatment

The treatment choice for cutaneous leishmaniasis depends on the Leishmania species, lesion location, number and size of lesions, and risk of mucosal involvement 7
Treatment success for CL should be monitored by clinical parameters: lesion flattening, >50% size decrease by 4-6 weeks, and reepithelization of ulcerative lesions by approximately 3 months 8

Mucosal Leishmaniasis (ML) Treatment

The Infectious Diseases Society of America recommends that all persons with clinically manifest, metastatic American ML should receive systemic antileishmanial therapy, with options including pentavalent antimonials, amphotericin B deoxycholate, liposomal amphotericin B, and miltefosine 12

Special Considerations

For therapeutic failure in CL, monitor lesions for 6-12 months after treatment, and consider additional therapy when new lesions develop, existing lesions worsen, or incomplete healing occurs by 3 months after treatment completion 8
For VL that doesn't respond to L-AmB, consider an alternative drug, higher dose, or longer course of L-AmB 10
In cases of HIV co-infection, initiate or optimize antiretroviral therapy as soon as the patient is stable enough to tolerate it, and consider combination therapy (e.g., L-AmB plus miltefosine) for refractory cases 10, 11

Treatment Decision Based on Geographic Risk for Mucosal Leishmaniasis

Risk Stratification

For immunocompetent adults with ≤5 lesions ≤5 cm, the initial management decision hinges on whether the infection was acquired in a region where Leishmania species are associated with a high risk of mucosal leishmaniasis (ML) 13, 14, 15.
High‑ML‑risk regions (New World): Infections acquired in Latin America where L. braziliensis, L. panamensis or L. guyanensis are endemic should be treated systemically even when lesions appear simple or are healing 14, 15, 16.
Low‑ML‑risk regions (Old World or non‑ML New World species): When the causative species are L. major, L. tropica or L. mexicana and lesions are healing spontaneously, observation without pharmacologic therapy is acceptable if the patient consents 14, 15, 16.
The potential benefits and harms of immediate treatment versus watchful waiting must be discussed with the patient in high‑risk settings 14.

Systemic Therapy (High‑Risk Cases)

Recommended systemic agents include oral miltefosine, liposomal amphotericin B, pentavalent antimonials, and amphotericin B deoxycholate 13, 17.
Pentavalent antimonials (sodium stibogluconate): 20 mg SbV per kg body weight per day administered intravenously or intramuscularly for 20 days 13.
In the United States, pentavalent antimonials are available only through a CDC‑sponsored investigational new‑drug (IND) protocol 13.

Local Therapy (Low‑Risk Cases)

Preferred modalities for simple Old‑World lesions are:
- Intralesional pentavalent antimonials (with or without cryotherapy) 13, 17, 14
- Heat therapy or cryotherapy 15
- Topical paromomycin‑containing ointments 15
- Photodynamic therapy or laser treatment 17
Prior to any local intervention, the ulcer’s eschar should be debrided and any secondary bacterial infection treated to optimize therapeutic effect 13, 17.
Intralesional injections should be avoided on anatomically sensitive sites (e.g., fingers, nose, ears, eyelids, perioral area) where vascular compromise is a concern 13.

Indications for Systemic Therapy in Low‑Risk Settings

Local therapy is impractical to deliver 13.
Rapid healing of large or cosmetically/ functionally important lesions is desired 17.
Lesions are located on cosmetically sensitive areas 14.

Essential Management for All Patients

Wound care: Provide standardized wound‑care instructions and document lesion evolution 13, 16.
Patient education: Counsel patients on signs of treatment failure or relapse and on ML warning symptoms (persistent nasal congestion, nosebleeds, hoarseness, septal perforation) 13, 17, 15.
Active monitoring schedule:
- Perform clinical examinations—including nasal and oropharyngeal assessment—periodically for up to 1 year; extend follow‑up to at least 2 years for individuals at increased ML risk 13, 15, 16.
Re‑evaluation: If observation is elected, reassess regularly and consider initiating therapy if lesion healing does not progress as expected 13, 14, 15.

Monitoring Treatment Response

Clinical criteria alone guide response assessment:
- Lesion flattening with >50 % reduction in size by 4–6 weeks 13, 17.
- Re‑epithelialization of ulcerative lesions by approximately 3 months 13, 17.
- Parasitologic testing is not required when lesions appear to be healing 13, 17.
- Healing may continue after therapy completion, especially for large ulcerative lesions 13, 17.
Continue lesion surveillance for 6–12 months post‑treatment; initiate additional therapy if new lesions arise, existing lesions worsen, or healing remains incomplete by 3 months 13, 17.

Critical Pitfalls to Avoid

Do not assume spontaneous healing for New‑World infections from ML‑risk regions; untreated disease can progress to destructive mucosal involvement 13, 15, 16.
Miltefosine must not be prescribed without confirming a negative pregnancy test and ensuring effective contraception for the patient during therapy and for 5 months thereafter 13.
Avoid intralesional therapy on anatomically sensitive areas where vascular compromise could occur 13.
Serologic assays are insufficiently sensitive and specific for diagnosing cutaneous leishmaniasis and should not be relied upon 15, 16.
Never omit nasal/oropharyngeal examination during follow‑up, as early mucosal disease may be asymptomatic 13, 15.